InnerSpace Improves Cart Security and Efficiency with the InterConnect Lock System

InnerSpace, a Solaire Medical Company, today announced the launch of the InterConnect Lock system.

When connected to Wi-Fi and the InnerSpace Smart Solutions cloud-based platform, InterConnect Lock Plus allows administrators to manage the security of the cart fleet remotely from anywhere. The InterConnect Lock stores up to 9,800 individual users and administrator codes per fleet and features an OLED display screen.

The InterConnect Lock has an OLED screen and keypad designed for touch responsiveness, even when users are wearing gloves. The low-gloss, textured keypad is resistant to scratching and damage from cleaning.

“InterConnect provides healthcare administrators with more information and a more secure and efficient experience,” said Ben Barber, CEO, InnerSpace. “Paired with Smart Solutions, InterConnect Plus makes it easy to change security credentials and auto-lock times as well as identify who has access to each cart. Being able to manage credentials with the stroke of a key saves time and provides added security at the cart level.”

The Wi-Fi connected InterConnect Plus allows users to submit a request to team members to facilitate cart maintenance and restocking. Automatic alerts are provided for low battery and lost network connection. A downloadable report tracks cart access, alerts and users. In the event of a power outage, data is retained and automatically uploaded when power is restored.

“The need for this type of lock product has been around for a long time, but it’s been cost prohibitive,” Barber said. “In many cases, a WiFi-enabled lock could be double the cost of a cart. That upfront cost priced past solutions out of the market. Our cloud-based subscription service offers a more affordable option that also saves administrators time managing cart fleet security.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy